Abstract
Diabetes increases the risk of cardiovascular disease; however, this risk is further increased as a result of other factors. This observation is particularly relevant with regard to lipid abnormalities. Although diabetic dyslipidemia is characterized by hypertriglyceridemia, low HDL-cholesterol, and small dense LDL particles, the main determinant of the role of dyslipidemia in the prognosis of diabetics is LDL cholesterol. In recent years, LDL cholesterol targets have become progressively lower, and most current recommendations establish an LDL cholesterol target of <70 mg/dL for diabetics. This target can only be achieved using potent statins at adequate doses. Although it has been suggested that statins may interfere with glycemic metabolism, the benefits of reducing LDL cholesterol by statins are much greater than this possible deleterious effect.
Rosuvastatin is one of the most potent statins available. Several studies have shown that it effectively reduces LDL cholesterol to recommended targets in diabetics. Moreover, rosuvastatin modestly increases HDL cholesterol and decreases triglycerides. The risk of side effects is low, as is the risk of interactions with other drugs.
In this manuscript, the efficacy and safety profile of rosuvastatin in diabetic population is reviewed.
Keywords: Diabetes, efficacy, HDL-cholesterol, LDL cholesterol, lipid profile, lipids, rosuvastatin, safety, statins, total cholesterol, treatment, triglycerides.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Rosuvastatin and Diabetes: When the Evidences Talk
Volume: 11 Issue: 2
Author(s): Vivencio Barrios and Carlos Escobar
Affiliation:
Keywords: Diabetes, efficacy, HDL-cholesterol, LDL cholesterol, lipid profile, lipids, rosuvastatin, safety, statins, total cholesterol, treatment, triglycerides.
Abstract: Diabetes increases the risk of cardiovascular disease; however, this risk is further increased as a result of other factors. This observation is particularly relevant with regard to lipid abnormalities. Although diabetic dyslipidemia is characterized by hypertriglyceridemia, low HDL-cholesterol, and small dense LDL particles, the main determinant of the role of dyslipidemia in the prognosis of diabetics is LDL cholesterol. In recent years, LDL cholesterol targets have become progressively lower, and most current recommendations establish an LDL cholesterol target of <70 mg/dL for diabetics. This target can only be achieved using potent statins at adequate doses. Although it has been suggested that statins may interfere with glycemic metabolism, the benefits of reducing LDL cholesterol by statins are much greater than this possible deleterious effect.
Rosuvastatin is one of the most potent statins available. Several studies have shown that it effectively reduces LDL cholesterol to recommended targets in diabetics. Moreover, rosuvastatin modestly increases HDL cholesterol and decreases triglycerides. The risk of side effects is low, as is the risk of interactions with other drugs.
In this manuscript, the efficacy and safety profile of rosuvastatin in diabetic population is reviewed.
Export Options
About this article
Cite this article as:
Barrios Vivencio and Escobar Carlos, Rosuvastatin and Diabetes: When the Evidences Talk, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020007
DOI https://dx.doi.org/10.2174/1871525711311020007 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Imaging Techniques as an Aid in the Early Detection of Cardiac Amyloidosis
Current Pharmaceutical Design Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Medicinal Chemistry Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews Molecular Genetics of Polycystic Ovary Syndrome: An Update
Current Molecular Medicine Impact of Periconceptional Undernutrition on the Development of the Hypothalamo-Pituitary-Adrenal Axis: Does the Timing of Parturition Start at Conception?
Current Drug Targets Sesbania: A Prospective Candidate to be Excavated for Anticancer Drugs
The Natural Products Journal Synthesis and Antioxidant Activity of 1,2,4-Triazole linked Thieno[2,3- d]pyrimidine Derivatives
Letters in Drug Design & Discovery Editorial (Thematic Issue: Mental Diseases in Medicinal Chemistry: From Synthetic and Natural Drugs to their Therapeutic Treatments)
Current Topics in Medicinal Chemistry Cardiac Rehabilitation Outcome Following Percutaneous Coronary Intervention Compared to Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Heme Oxygenase-1: A Potential Antihypertensive Target?
Current Hypertension Reviews C-Reactive Protein and Atherosclerosis: An Update
Vascular Disease Prevention (Discontinued) Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Biological Roles of the Eclectic Chromogranin-A-derived Peptide Catestatin
Current Medicinal Chemistry Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design